Subsequent Event	6 Months Ended
Jun. 30, 2022
Subsequent Events [Abstract]
Subsequent Event	13. Subsequent Event In July 2022, the Company entered into an agreement to develop and seek regulatory approval of a companion diagnostic for tovorafenib (DAY101) in pLGG with BRAF fusions or BRAF V600 in the United States and the European Union markets. The agreement contains non-refundable, non-creditable development, regulatory submissions and approvals milestone payments totaling up to $15.0 million payable to the vendor upon the successful completion of such milestones.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI https://asc.fasb.org/topic&trid=2122774

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration